Clinical trial
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn…
NCT00343044 · Benaroya Research Institute, Other · Completed
Key facts
| NCT number | NCT00343044 |
|---|---|
| Title | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers |
| Official title | Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers |
| Lead sponsor | Benaroya Research Institute, Other |
| Collaborators | GlaxoSmithKline Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Topotecan, Bevacizumab |
| Enrollment | 40 |
| Start date | Jun 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Aug 1, 2011 |
| First posted | Jun 22, 2006 |
| Last update posted | May 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: